"Cautious but open." Of five possible answers, that is the one the most people chose, and if it is the one you would have chosen, you already know the feeling.
It is not fence-sitting. Often it belongs to someone who has watched a person they love cycle through medications that did little, and who has seen "ketamine" used in enough ways to know it carries no single clean meaning. You are not waiting to be talked into anything. You are waiting for someone to say precisely what is on offer.
We put ketamine-based treatment of depression or PTSD to 443 survey respondents and recorded their gut response. Cautious but open drew 34 percent of them, more than any other answer. Skeptical came next at 21 percent, hopeful or curious and unfamiliar tied at 18 percent apiece, and negative reactions were 9 percent. So 51 percent lean toward yes and fewer than one in ten lean firmly away. Final validation is done, and the shape holds: if you are cautious, you are standing with the biggest group in the room.
Is it approved, or is this a workaround?
Both, depending on which version is on the table.
Esketamine, which is sold as Spravato, went through FDA review and won approval for depression that has held on through other treatment. Approval means a regulator examined the evidence for that specific use and cleared it, with conditions on how and where it may be given. Generic ketamine for depression has not been through that process. That does not make it illegitimate, but it is a different kind of claim.
Is this the same drug people misuse?
Same molecule, and pretending otherwise would insult you. Ketamine is a hospital anesthetic that is also used recreationally. What separates the medical version is the dose, the setting, the supervision, and an accountable prescriber. Your suspicion is why the approved version is built the way it is.
Where does it happen, and who is in the room?
For the approved form, a certified clinic, where the patient handles the spray under a health professional's eye. If someone describes it as something you do alone at home, they are describing something else.
What the monitoring period actually means
After each dose you stay under observation before you may leave, and someone else drives you home. That rule does not mean the treatment is reckless. The effects can include feeling detached or altered for a time, and regulators decided a qualified person should be present while that passes; the supervision is written into the approval, not added for show. Brain Recovery Centers walks through a typical Spravato visit, start to finish if you want the concrete picture.
What it is approved to treat, and what it is not
The approval covers depression that earlier treatments did not adequately relieve. Our survey paired depression with PTSD because that is how the idea circulates, not because the approval covers both; it does not. If anyone offers this for something outside the label, slow down and ask a clinician why.
Three different things, one word
- The approved nasal spray: esketamine, dosed only in certified offices with staff observing, then a monitoring stretch, and never taken home.
- Off-label IV ketamine: generic ketamine infused at a clinic with staff present. Its approval is as an anesthetic, so depression use is off label, which is legal and common in medicine but has not cleared the review esketamine did.
- At-home telehealth ketamine: prescribed remotely, usually as a lozenge or tablet, and taken with nobody around. It is the grayest of the three, and none of the supervision described above applies to it.
"Which of those three is this?" is a fair opening question for any provider, and the answer tells you a lot.
What people said they need before they say yes
We also asked what would actually move someone. Their own doctor's recommendation was the answer for 74 percent; an ad managed 2 percent and a podcast host 1. FDA approval would decide the question or weigh heavily for 59 percent, and coverage would do the same for 65 percent; insurance also sat in the top two provider criteria of 85 percent.
So ask for three things: your own doctor's read, a plain statement of whether the proposal is the approved version or an off-label one, and coverage in writing before you begin.
You are allowed to want it covered
When our survey offered a straight tradeoff, half of respondents, 51 percent, picked the insured path even with extra hoops. Fewer, 23 percent, would rather pay and start sooner, and another 26 percent were unsure. Asking about cost does not make you unserious about getting better.
If you had never heard of any of this
You have company. When we described the idea, the concept itself was news to 18 percent of respondents. Spravato, as a name, was a blank for 73 percent; 21 percent more knew the word but had no clue what it named.
Our open-ended search question drew 319 answers and almost no drug names; people wrote "depression medicine alternatives," "someone please help me," "ptsd treatments." You do not need the vocabulary either. Walk in with how you feel and what has not worked, and let the clinician supply the names.
The part nobody can promise you
Not this article, not a clinic, not a regulator. Approval means a treatment was reviewed and cleared for a use, not that it will work for you, and anyone implying otherwise is selling. Whether any of this fits depends on your diagnosis, history, past treatments, and current medications, which is a clinician's call to make.
If depression has taken you somewhere darker than a treatment decision, please do not sit with it alone tonight. Anywhere in the U.S., call or text 988. The Lifeline costs nothing, keeps your call private, and has people on duty at every hour, whether you fear for yourself or for someone else.
Methodology
As publisher, we commissioned and financed this survey. Pollfish gathered 443 responses from its consumer panel, adults 18 to 64 in Nebraska, Indiana, Illinois, Kansas, Minnesota, and five other Midwest states, before closing on June 23, 2026. We publish top-line results alone, and select-several questions can sum above 100. Every number cleared the panel's final validation.